A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Poziotinib|DRUG: T-DM1
Sponsor: Spectrum Pharmaceuticals, Inc